NASDAQ:PRTA - Prothena Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $47.38
Forecasted Upside: -3.06 %
Number of Analysts: 9
Breakdown:
0 Sell Ratings
1 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$48.87 As of 06/24/2021 01:00 AM ET

▲ +0.76 (1.58%)

1 month | 3 months | 12 months

Get New Prothena Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for PRTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTA

^$47.38

▼ -3.06% Downside Potential

This price target is based on 9 analysts offering 12 month price targets for Prothena in the last 3 months. The average price target is $47.38, with a high forecast of $62.00 and a low forecast of $29.00. The average price target represents a -3.06% upside from the last price of $48.87.

Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Prothena. This rating has held steady since December 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
3 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

1/1/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

3/31/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/29/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/27/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/26/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/26/2021

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/25/2021

0 strong buy ratings
8 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/18/2021	Bank of America	Upgrade	Underperform ➝ Neutral	$12.00 ➝ $49.00	High
6/11/2021	Royal Bank of Canada	Boost Price Target	Outperform	$28.00 ➝ $50.00	Medium
6/10/2021	HC Wainwright	Boost Price Target	Buy	$33.00 ➝ $58.00	High
6/8/2021	Oppenheimer	Boost Price Target	Positive ➝ Outperform	$45.00 ➝ $54.00	High
6/8/2021	Cantor Fitzgerald	Boost Price Target	Overweight	$43.00 ➝ $62.00	High
6/1/2021	Oppenheimer	Boost Price Target	Outperform	$40.00 ➝ $45.00	High
5/26/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage	Buy	$39.00	High
5/26/2021	Citigroup	Initiated Coverage	Buy		High
5/12/2021	Oppenheimer	Boost Price Target	Outperform	$35.00 ➝ $40.00	High
3/15/2021	Jefferies Financial Group	Boost Price Target	Buy	$30.00 ➝ $38.00	High
3/2/2021	Oppenheimer	Reiterated Rating	Buy	$35.00	Medium
2/26/2021	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$14.00 ➝ $28.00	Medium
2/12/2021	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$15.00 ➝ $30.00	Low
2/4/2021	HC Wainwright	Boost Price Target	Buy	$22.00 ➝ $33.00	Low
2/2/2021	Oppenheimer	Boost Price Target	Outperform	$25.00 ➝ $35.00	Low
2/2/2021	BTIG Research	Upgrade	Neutral ➝ Buy	$29.00	Low
12/10/2020	Oppenheimer	Boost Price Target		$20.00 ➝ $25.00	Low
12/7/2020	HC Wainwright	Initiated Coverage	Buy	$22.00	Low
10/21/2020	Cantor Fitzgerald	Boost Price Target	Positive ➝ Overweight	$20.00 ➝ $24.00	High
9/13/2020	Oppenheimer	Reiterated Rating	Buy	$18.00	High
7/8/2020	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$16.00	High
5/13/2020	Oppenheimer	Reiterated Rating	Hold		High
5/10/2020	Nomura	Reiterated Rating	Buy	$19.00	High
4/23/2020	Oppenheimer	Reiterated Rating	Hold		Low
1/1/2020	Nomura Securities	Reiterated Rating	Buy	$19.00	Low
12/22/2019	Evercore ISI	Reiterated Rating	Buy	$14.00	High
11/27/2019	Evercore ISI	Upgrade	In-Line ➝ Outperform		Low
11/19/2019	Evercore ISI	Upgrade	In-Line ➝ Outperform	$14.00	High
5/31/2019	Barclays	Reiterated Rating	Sell	$9.00	Low
5/16/2019	Cantor Fitzgerald	Reiterated Rating	Overweight		High
3/4/2019	Cantor Fitzgerald	Initiated Coverage	Overweight	$13.77	High
11/23/2018	Cantor Fitzgerald	Reiterated Rating	Overweight		High
11/11/2018	Oppenheimer	Reiterated Rating	Hold		High
8/8/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$18.00	Low
6/15/2018	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Buy	$14.00 ➝ $18.00	High
5/25/2018	Oppenheimer	Reiterated Rating	Hold		Low
5/21/2018	Barclays	Downgrade	Equal Weight ➝ Underweight	$12.00	High
5/9/2018	Oppenheimer	Reiterated Rating	Hold		High
4/24/2018	Nomura Securities	Lower Price Target	Buy ➝ Buy	$87.00 ➝ $19.00	High
4/24/2018	Wedbush	Lower Price Target	Neutral	$46.00 ➝ $13.00	High
4/24/2018	BTIG Research	Downgrade	Buy ➝ Neutral	$77.00	High
4/24/2018	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy ➝ Buy	$78.00 ➝ $16.00	High
4/24/2018	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$69.00 ➝ $14.00	High
4/23/2018	Oppenheimer	Downgrade	Outperform ➝ Hold		High
4/23/2018	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$87.00	High
4/23/2018	Barclays	Downgrade	Overweight ➝ Equal Weight		High
4/23/2018	Jefferies Financial Group	Downgrade	Buy ➝ Hold		High
4/5/2018	Barclays	Lower Price Target	Overweight ➝ Overweight	$70.00 ➝ $50.00	Medium
3/21/2018	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		High
3/21/2018	Cantor Fitzgerald	Reiterated Rating	Overweight	$69.00	High
3/21/2018	Oppenheimer	Set Price Target	Buy	$70.00	High
2/15/2018	Oppenheimer	Set Price Target	Buy	$70.00	High
2/4/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$65.00	High
12/20/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$65.00	Medium
12/4/2017	Oppenheimer	Set Price Target	Buy	$70.00	High
11/20/2017	Wedbush	Downgrade	Outperform ➝ Neutral	$75.00 ➝ $55.00	N/A
11/9/2017	Oppenheimer	Reiterated Rating	Buy	$70.00	N/A
10/23/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$73.00	N/A
10/2/2017	Jefferies Financial Group	Reiterated Rating	Buy	$100.00	Low
10/2/2017	SunTrust Banks	Reiterated Rating	Buy	$75.00	Low
10/1/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		Low
9/29/2017	Royal Bank of Canada	Reiterated Rating	Buy		High
9/29/2017	BTIG Research	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $77.00	High
9/28/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$79.00	Medium
9/14/2017	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$87.00	High
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$83.00	High
7/10/2017	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$100.00	Medium
7/6/2017	Oppenheimer	Reiterated Rating	Outperform	$70.00	Low
5/19/2017	BTIG Research	Initiated Coverage	Buy	$80.00	High
5/16/2017	Piper Jaffray Companies	Reiterated Rating	Buy		Medium
5/11/2017	Oppenheimer	Set Price Target	Buy	$70.00	Low
4/12/2017	Cantor Fitzgerald	Initiated Coverage	Overweight	$86.00	High
4/12/2017	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight	$69.00	Medium
4/6/2017	Oppenheimer	Set Price Target	Buy	$70.00	Low
4/3/2017	Wedbush	Reiterated Rating	Outperform	$77.00	High
3/22/2017	Oppenheimer	Reiterated Rating	Buy		Low
3/1/2017	Nomura Instinet	Initiated Coverage	Buy ➝ Buy	$87.00	N/A
3/1/2017	Nomura Securities	Initiated Coverage	Buy		N/A
2/15/2017	Wedbush	Reiterated Rating	Outperform	$77.00	N/A
12/20/2016	SunTrust Banks	Initiated Coverage	Buy	$75.00	N/A
12/6/2016	Wedbush	Reiterated Rating	Outperform	$77.00	N/A
11/10/2016	Wedbush	Reiterated Rating	Outperform	$77.00	N/A
11/3/2016	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$73.00	N/A
10/31/2016	Wedbush	Reiterated Rating	Outperform	$77.00	N/A
9/27/2016	Credit Suisse Group	Reiterated Rating	Buy	$65.00	N/A
9/26/2016	Wedbush	Reiterated Rating	Outperform	$77.00	N/A
9/11/2016	Credit Suisse Group	Reiterated Rating	Buy	$65.00	N/A
8/4/2016	Barclays	Boost Price Target	Overweight	$60.00 ➝ $70.00	N/A
8/4/2016	UBS Group	Reiterated Rating	Buy	$73.00	N/A
8/3/2016	Wedbush	Reiterated Rating	Outperform	$77.00	N/A
7/18/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$95.00	N/A
7/12/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A
7/5/2016	Wedbush	Reiterated Rating	Outperform	$77.00	N/A

(Data available from 6/24/2016 forward)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

Today's Range

Now: $48.87

$48.32

$53.73

50 Day Range

MA: $31.24

$21.63

$57.65

52 Week Range

Now: $48.87

$9.39

$59.74

Volume

696,615 shs

Average Volume

452,533 shs

Market Capitalization

$2.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Frequently Asked Questions

What sell-side analysts currently cover shares of Prothena?

The following sell-side analysts have issued stock ratings on Prothena in the last twelve months: Bank of America Co., BTIG Research, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for PRTA.

What is the current price target for Prothena?

8 Wall Street analysts have set twelve-month price targets for Prothena in the last year. Their average twelve-month price target is $47.38, suggesting a possible downside of 3.1%. Cantor Fitzgerald has the highest price target set, predicting PRTA will reach $62.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $29.00 for Prothena in the next year.
View the latest price targets for PRTA.

What is the current consensus analyst rating for Prothena?

Prothena currently has 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRTA will outperform the market and that investors should add to their positions of Prothena.
View the latest ratings for PRTA.

What other companies compete with Prothena?

Other companies that are similar to Prothena include Mirati Therapeutics, United Therapeutics, Ascendis Pharma A/S, Evotec, Sarepta Therapeutics, Biohaven Pharmaceutical, Ultragenyx Pharmaceutical, Perrigo, I-Mab, Schrödinger, TG Therapeutics, Ionis Pharmaceuticals, Legend Biotech, Reata Pharmaceuticals and Apellis Pharmaceuticals.

How do I contact Prothena's investor relations team?

Prothena's physical mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The biotechnology company's listed phone number is 011-353-1236-2500 and its investor relations email address is [email protected] The official website for Prothena is www.prothena.com.